Latest / Newcomer Pod / A New Dimension (w/Nan Li, Adam Goulburn, and Zavain Dar)
Transcript
- 0:05Welcome everybody, Welcome to Dead cat.
- 0:14This is Eric newcomer, very exciting podcast episode.
- 0:19I think I was the first, I was just checking this.
- 0:22I was the first to write about Dimension.
- 0:25New, 350 million dollar fund and I have the entire team, right?
- 0:29Or the three. Three founders, at least here.
- 0:32Zov and are and Adam. Goulbourne both from Lux and
- 0:37then non Lee from obvious. Ventures.
- 0:40Thanks guys for coming on. I really appreciate it.
- 0:42Thanks for having us, dude. And say who you are at the
- 0:45beginning. When you start talking for the
- 0:46first time as people start to learn your voices and I'm just
- 0:50going to throw questions on. You guys can fight about who
- 0:52gets to answer what but why did you decide to start a new Fund
- 0:57in the first place? I mean, you guys were cool
- 0:59venture. Ons, like why go independent?
- 1:03This is oven, by the way, thanks for having us in so many ways.
- 1:06We kind of grew up in Industry. We were best friends.
- 1:10Whether Adam and Don would say that about me, TBD not and I
- 1:14taught at Stanford for four or five years.
- 1:16We first met at Innovation Endeavors.
- 1:18We were roommates in Oakland for a number of years before Oakland
- 1:22was cool. And then Adam and I actually met
- 1:24at JP Morgan in San Francisco in 2014.
- 1:27And also very quickly became good friends with a nine month.
- 1:30Of meeting Adam. He had recruited me over to
- 1:32Locks and then we poem digital dark crafts together.
- 1:35We built our biotech practices at obvious where non went and
- 1:39was one of the founding investors and ultimately a GP
- 1:41and and it locks as well. And so, there's a chance.
- 1:44How many years ago did the idea of a the three of us might start
- 1:48a fun first. By the way, I will say at the
- 1:522014 JPMorgan, Healthcare conference.
- 1:55This is Adam. By the way, you'll know my voice
- 1:57but the mishmash of Australian and New York and by watching
- 2:02Hawkins door. So it's a blend.
- 2:04But that, that same conference, I met my wife and I met Zoe of
- 2:07in the space of, wow. He met his life Port partner and
- 2:13then less importantly, his work partner wind within one hour
- 2:16which yeah. Insane.
- 2:18So when you make all your portfolio companies, go public
- 2:21with JP, you know you'll know yeah.
- 2:24Very close to the bank like is the bank at deal flow out of
- 2:27this or not. You'll plug that way.
- 2:30We're obviously close to the bank.
- 2:32I was very close to only. They were invited to the
- 2:35wedding. Yeah.
- 2:38When did you first think we might do a fun together, or what
- 2:42was this? Like text thread for a long time
- 2:45or this is non. By the way, I really think it
- 2:48was a 10-year long conversation. You know, it was sort of the
- 2:51slow build of growing up in the industry together, getting to
- 2:55know each other definitely being on text threads about this space
- 2:59and what we're seeing You're catching up every time we were
- 3:03in the same city or at a conference.
- 3:05So it was this really gradual build.
- 3:07I think, especially through the sort of Boom period of 2020
- 3:122021. Some of the earlier companies
- 3:14that we worked with were scaled and some of them went public and
- 3:18the space just really exploded in activity.
- 3:21So I think there is a forcing function of the realization
- 3:24that. Wow, this seemingly small area
- 3:27that we used to cover when we were coming up in the industry.
- 3:30Together is now reorganizing the entire industry and we're seeing
- 3:34signs of that everywhere. So the three of us just kind of
- 3:36looked at each other and said you know our ability to cover
- 3:39this as one member of this broad firm is really limited and the
- 3:45space is so large and there's so much opportunity that we just
- 3:48felt like we were doing a disservice by get the sector
- 3:50deserves its own fund and we just felt if we didn't do it you
- 3:54know the three of us know each other.
- 3:55Well we've been doing work for a long time.
- 3:58If we don't do it will really regret Not making that move,
- 4:01right? It's more fun to think of it as
- 4:03a three friends go off and Silicon Valley version of raise
- 4:07a you know instead of a band you raise a fund and get 350 million
- 4:12dollars to chase Your Wildest Dreams.
- 4:13But yeah, I mean, you guys are all sort of DieHard, Believers
- 4:19in this sort of thesis and that's really what I want, you
- 4:21know, the episode to be about because I think this is a cool
- 4:25fun where it's like, okay, we are, I mean, you kept evoking in
- 4:29our conversation, Before this Ribbit Capital, you know, which
- 4:32is a very successful Focus fun, very different space that went
- 4:36all in on fintech and crypto and a wildly successful fund.
- 4:39And so I like this idea that you guys see a space that sort of
- 4:43coming and want to define the firm around it.
- 4:46So you know, it's life sciences and Technology I sort of get it
- 4:50but explain to me like what is the organizing principle of the
- 4:54investment thesis of Dimension? Will it?
- 4:57I think you're spot on when we laughed and we had a kind of
- 5:00Asians about leaving and then when we think about what we can
- 5:02become it's what making multitude.
- 5:04But Ribbit it's what's Anil and Mike have done with amplify.
- 5:07Its but cursing, green did with DTC and 4Runner even map and
- 5:11Fred a paradigm in crypto and met three.
- 5:13There's a chance before things are obvious to build a firm and
- 5:16not only capture the best entrepreneurs and support and
- 5:18Steward them. But also be a little bit of a
- 5:20rallying call for the broader ecosystem.
- 5:23I think if we do it right at the mentioned, that's ultimately
- 5:25what we want to do and what we want Dimension to become a
- 5:28forum, kind of in that mode. Oh, Dan in that ilk, what we
- 5:32saw. And we'll keep it high level,
- 5:33but double click in any and all questions.
- 5:35Eric is that the leading practitioners on both sides?
- 5:39Whether they were kind of machine, learning researchers
- 5:41and computer scientists at deepmind or open AI or metal AI
- 5:45or Microsoft, research, or diesel research.
- 5:48They were one by one uniformly and independently building out
- 5:51their own weapons capabilities and then simultaneously
- 5:55attacking biology and chemistry's.
- 5:57Most vexing problems really over the last three or four decades
- 6:00Kids with increasing traction and adopters Alpha fold.
- 6:03There's a multitude of other examples, we can point to, but
- 6:06that was happening on the computer science side and then
- 6:08conversely on the molecular biology and the chemistry side,
- 6:12every leading research lab to go to a Harvard and Yale and
- 6:15Stanford and MIT as so on and so forth.
- 6:18All of them were increasingly fluent in software packages,
- 6:21like tensorflow. They were all coding on a
- 6:24regular daily basis in a way that even five years ago would
- 6:27have been pretty surprising. And, in 10 years ago would have
- 6:29been absolutely Solutely null. So the realization for us was
- 6:32that at the Two Poles, the leading experts were
- 6:36increasingly speaking each other's languages and capital
- 6:39markets were still entirely dichotomies today.
- 6:41If you're an investor you're either a software investor or
- 6:43you're a biotech investor, you're either investing in SAS
- 6:46and ARR sorts of companies or you're investing in single
- 6:50molecules and assets. But as the disciplines become
- 6:53increasingly affluent between themselves, the sorts of
- 6:56businesses that can be built are changing in and of themselves.
- 6:58And we had a chance to kind of bridge the Gap in really basic
- 7:01terms and I'm cribbing from lines that you guys have said,
- 7:05but the part of the idea here is that, you know, there are
- 7:08companies that did like drug research or whatever and they're
- 7:11there, the scientists. And then there were companies
- 7:13that had software engineers and their the tech companies and
- 7:17what you're seeing and what's already starting to happen, you
- 7:20know, is those two sets of people sort of work together and
- 7:24build a company? Right?
- 7:25Am I getting that right? And like why would I guess if
- 7:29we're sticking with the Drug development company example, in
- 7:32particular, why would a drug development company needs
- 7:35software Engineers? Look if you just kind of go back
- 7:37to the core unit of progress in life sciences is the experiment,
- 7:43it's were running experiments and that's what drug Discovery
- 7:45companies do and that's what scientific Labs do the rate of
- 7:50experimentation the quality of experiments and the cost have
- 7:53all sort of compounded exponentially over a decade.
- 7:57And the result of that is that lab today.
- 8:00You are just turning out tons of data sets on a daily basis and
- 8:04it's getting sort of unmanageable, so before
- 8:07experimentation was very manual. And in some ways artisanal where
- 8:11the scientists could read the output of an instrument, or an
- 8:13assay and just sort of infer what that meant and then go
- 8:16about designing the next experiment.
- 8:19But now the experiments are getting very high throughput.
- 8:22They're very cheap to run and labs are generating data streams
- 8:26that look kind of like internet platform companies.
- 8:30There are certain biotechs that we work with that generate more
- 8:32data per day than Twitter does and that's where sort of data
- 8:36science and software must come in it's really out of necessity.
- 8:40You know the way a modern LAB Works today looks nothing like
- 8:4420 years ago and it's really the result of a tremendous amount of
- 8:47progress and essentially every single type of molecular tool,
- 8:51the scientist would want to run. So if you think Eric then about
- 8:54the tools, the Technologies and the products that need to be
- 8:57built for the modern lab in the modern, Biotech.
- 9:01It's very different to what it was, you know, 10 or 20 years
- 9:03ago and for us informing Dimension.
- 9:06It was crazy that there wasn't a firm that could invest in what
- 9:10would be what we view as the next you know, product
- 9:14discovered drug Discovery engines that are out there a
- 9:16biologist, a chemist, and a computer scientist but also
- 9:20didn't help build and partner with companies and Founders that
- 9:23were building the tools and technology and software
- 9:24solutions that were powering those discoveries upstream and
- 9:27downstream. And so there's this.
- 9:30Newell, you know, language that goes between, you know, biotechs
- 9:34and their tools and Technologies products that they use that you
- 9:37need a from and a set of investors and partners that are
- 9:40multilingual across that entire Spectrum.
- 9:43Would you invest in a drug development company that says,
- 9:47okay we have a great like data software approach or do you want
- 9:51to stick to companies that are broadly, helping a bunch of
- 9:55different drug Discovery programs with software.
- 9:58That's shared across companies or Yeah, I guess is it only
- 10:02platforms, are you willing to go with this room or vertical
- 10:05company? We've already done both and say,
- 10:07even in our portfolio that that we just kind of announced this
- 10:10week on one end you'll get in Veta, which is exactly that drug
- 10:14Discovery platform, it's leveraging software, automation,
- 10:16next-gen Mass Spec in their case on the biology side but it's
- 10:20ultimately in the service of finding discovering and
- 10:23ultimately developing therapies for human disease.
- 10:26On the other end, the hat that I'm wearing right now.
- 10:28Science tools is from a company. Kaleidoscope IO.
- 10:31And that's a software company that's essentially building
- 10:34think of it as the GitHub for the modern and the evolving lab
- 10:37that. Now I'm kind of painted out
- 10:38where it's becoming increasingly interdisciplinary increasingly
- 10:41spread across both space and time.
- 10:43How do you kind of tag the metadata associated with the
- 10:46history of experiments that you've run?
- 10:48How do you make it increasingly reproducible, so on and so
- 10:51forth. And that's kind of the problem
- 10:52that Kaleidoscope. It's is solving, but it's
- 10:54exactly ultimately a SAS company.
- 10:57So it will be valued as a software company, this could all
- 10:59get Sort of wonky. So I want each of you just in a
- 11:03decade or like in two decades what sort of like the thing, the
- 11:07public gets out of this, you know, I feel like with AI which
- 11:10I've been talking a lot of on this podcast, I know touches
- 11:13your world or with the, you know, it's like, oh, we get
- 11:15cartoons of my, I get a cartoon of myself and I get to cheat on
- 11:18my homework or whatever, you know, it's fun because you can
- 11:20sort of see right away what me sort of the consumer is getting
- 11:25out of you. Sort of the futurist, can you
- 11:27each give me sort of I mean, because This, you touch a bunch
- 11:31of different types of ideas and Fields, like, you know what,
- 11:34something fun that you hope in a decade or two decades.
- 11:36Our Lives might be different because of this space and the
- 11:41Investments you want to do. I think a big one and this is
- 11:44already been happening. So it's not that much of a
- 11:47prediction, but really sort of a forecast of what's already begun
- 11:51to occur, is that because of all the new data sets that are
- 11:53coming online, our ability to Define diseases, will get
- 11:57sharper, and sharper. And when we look back after, A
- 12:00decade, we're going to realize that a lot of the diseases that
- 12:03are commonly referred to in known today we're too broad and
- 12:08this is already happening cancer where no one has cancer, they
- 12:10have these specific genetically defined sub indications of
- 12:14cancer. And those are treated as unique
- 12:17diseases and they're diagnosed that way.
- 12:19That same thing is going to happen across every major
- 12:21disease area fibrosis. Neuro inflammation, GI disease
- 12:27is essentially no one has Crohn's.
- 12:28No one has Alzheimer's Those are just shortcuts that we use
- 12:32because we don't know better yet.
- 12:35But right now, the next generation of Farmland, biotechs
- 12:38are using all of these experiments and assays to sort
- 12:41of build a data portfolio of these disease areas.
- 12:45And the vocabulary will totally change in a decade.
- 12:48When you say, like, no one has Crohn's.
- 12:50No one has Alzheimer. I mean, that's fascinating,
- 12:51like, the actual causes of those diseases are very different, or
- 12:55just the types of medicine that you would use to treat them as
- 12:59very different From the next yeah how we Define them.
- 13:02Like if I was to sum up in a sentence a little bit, what non
- 13:05just said, it's like the March towards personalized medicine.
- 13:09He's on the technology train, right?
- 13:11Technology is infusing into everything that we're doing from
- 13:14drug Discovery to running clinical trials to diagnosing
- 13:17and then ultimately commercializing.
- 13:19And so as you think about, you know, a future where we get
- 13:22better at targeting and Discovery, we get better at
- 13:25diagnosing and we get better at treating, that is that March
- 13:28towards personalized medicine. Right, as you define diseases
- 13:31better as you think about them as spectrum of diseases and
- 13:35then, you know, we end up in a world where, you know, hopefully
- 13:38we're a much healthier and treatable population and a lot
- 13:41of what goes on then, in the healthcare services is much more
- 13:43about being proactive, rather than reactive is it about the
- 13:46fact that I'm different from the next person and my genetics are
- 13:52different or it's the actual disease is different from the
- 13:56disease. Someone else is getting in
- 13:58disease is probably even the wrong word here.
- 14:00It bi is it about my unique genetic code or the it somewhat
- 14:04magical? It can be a little bit about and
- 14:06so is as kind of non mentioned that if you look at kind of the
- 14:10chronology of oncology cancer over the last two or three
- 14:12decades, it's essentially moved from a death sentence into
- 14:16increasingly, so kind of chronic and managed illness and a lot of
- 14:20that is because we've found the kind of subcategories that are
- 14:23consistent across the population but become more precise with the
- 14:27actual diagnosis of what the actual genetic.
- 14:29Condition is for the disease on the other hand.
- 14:32If you look back even maybe in the last month or two moderna
- 14:35and Merck kind of had a had a pet, a pretty meaningful
- 14:38approval on a personalized cancer vaccine or drug.
- 14:42That was an end of one kind of therapy.
- 14:44So it would look at Eric your particular mutation.
- 14:47God, forbid and then build at therapy based on your particular
- 14:51mutation as it relates to the rest of your kind of genetic
- 14:54code last name. All right, that's one.
- 14:58It's not a really they're not wisdom.
- 15:00Bags because it's like, oh man, keeping me alive.
- 15:02When I'm, you know, hopefully much older.
- 15:04It's, we spent the first six months cohabitating in squatting
- 15:08out of Chris from Runway his office.
- 15:10Yeah, so we're listening. He's a good friend way back to
- 15:12him. And been fortunate to kind of
- 15:13lead the seed while at our prior firm.
- 15:15He's a good friend and we told him to stay there for 24 hours,
- 15:18and we ended up being there for half a year, but we listen to
- 15:22his podcast and he had all these kind of amazing kind of
- 15:24anecdotes about, you know, what's hap CBT look like for
- 15:26video or media and so on and so forth?
- 15:28And candidly not I mention this because the modern kind of wet
- 15:31lab today is the largest producer of data may be only on
- 15:35par or surpassed by the have hyper scalars today.
- 15:38And so, it's very provocative to kind of think about what does
- 15:41chap, CBT, or GPT? X look like against
- 15:46population-wide genetic data look like against metabolomic or
- 15:49proteomic orphan ohmic data. And these are the sorts of
- 15:52problems. I think that we're just on the
- 15:54precipice of starting to think about an answer and again, you
- 15:56get these bread crumbs like open a Or metal a eye opening up a
- 16:02wet bench facility in New York to attack these sorts of
- 16:04problems, we can postulate, it may well be 20 30 years in line,
- 16:09or maybe even 10 years at the Adelaide, you Eric, feel sick,
- 16:12you go in, you get some sort of Advanced next-gen Diagnosis of
- 16:16your illness. And then at the point of care
- 16:18wherever you are a custom end of one molecule, whether that's a
- 16:22kind of a small molecule or an antibody so on and so forth.
- 16:24It gets printed for you for your disease at that State, in the
- 16:28moment in time and you Take it and you're healed.
- 16:31I can't tell you if that's a hundred years from now or if
- 16:34that's 10 years from now, but scientifically and
- 16:37technologically, there's no reason why that's not possible.
- 16:40So this is sort of our second bucket where it's like okay
- 16:42applying sort of generative, AI tools to sort of genetic
- 16:47sequence. And I will, I'm gonna somebody
- 16:49come up with a third but I wanted to ask, like, the whole
- 16:52like folded home or like, when there was a whole like proteins.
- 16:57I remember, I literally had it, like, I was part of this, you
- 16:59know? I credit.
- 17:00I was, you know, streaming on some laptop back in the day like
- 17:03study and fold at home. It feels like this technology
- 17:06fits into that or a lie and then certainly the you guys know
- 17:08what's going on with the whole protein folding thing, what
- 17:12happened with that? How does for the current state
- 17:14of Technology help? Well, I mean, if only, I were,
- 17:17you don't know where is this too?
- 17:19Weird of a quick? No, no.
- 17:20It's it definitely is in the lineage of all the sort of
- 17:24protein folding and a I break through the hear about today for
- 17:28that home was a really successful essentially A
- 17:30Federated computation project and protein folding has always
- 17:34been one of the most computationally intensive
- 17:36exercises. So for computer scientists, it
- 17:38was always this Gauntlet of, you know, can we drive artificial
- 17:42intelligence and drives computation into the point where
- 17:45we can calculate the sort of native protein structure?
- 17:49Given the sequence given given amino acid sequence and that has
- 17:54always been the hardest challenge in in these different
- 17:57tests of a I you know, computer vision and Nation of images was
- 18:01one test. You know, beating a human at
- 18:03chess was a test, beating humans at go was a test.
- 18:05But for accurate, protein structure.
- 18:08Predictions has always been the one that that was unachievable
- 18:12until very recently with, with deepmind of the work they did
- 18:15with Alpha fold, but you're Eric, your contributions to
- 18:18that, definitely like it was part of the same competition.
- 18:21It's essentially the same challenge, you know?
- 18:22Turn the video Acid sequence solve this problem or it's just
- 18:25they're much better at, like, crunching through it now.
- 18:28I think it's the earliest, Innings of right there is real
- 18:31value in being able to go from sequence to structure but one of
- 18:35the things we like to say internally and we wrote a
- 18:38letter, is it in a biology is the most complex and beautiful
- 18:41machine ever created, right? And so as you think about
- 18:44protein structure, you know, there's primary tertiary or
- 18:47secondary and tertiary and quaternary structures, right?
- 18:50There's modifications, there's complexes.
- 18:52So there are more levels to go here in terms of what technology
- 18:57can do and deliver in terms of really good.
- 18:59I'm from, you know, sequence to structure and then to
- 19:02ultimately, to function and then well, out into the future of the
- 19:06ability to sort of simulate various aspects of biology, but
- 19:10I don't want to diminish from how powerful, you know, this
- 19:13moment in time is, you know, similar to, you know, sequencing
- 19:17The genome similar to, you know, crispr, which is now permeated
- 19:21through every modern lab and every lab on the planet, right?
- 19:24These are a specific moment in time and it's not just those
- 19:27three. There are more and more that are
- 19:29coming. That are here and that's why
- 19:31we're really excited. Can you tell which one of us is
- 19:33the biologist? Yeah, you there's a little
- 19:38difference to the PHD everyone. So I which I think is Adam,
- 19:42right? The crisper, I mean, it fits
- 19:45into my sort of folding@home. I mean, I think you know as sort
- 19:48of a layperson just following this industry.
- 19:50There are moments where sort of, I don't know, the technology of
- 19:54biology sort of like cracks in. We all get excited about it and
- 19:57then sometimes I feel like we just don't get like the up.
- 19:59Earl's like what happened. So like yeah with crisper I
- 20:03remember in 2014 I was writing like very enthusiastically I
- 20:08think like alumina is an important company.
- 20:10Now in your space and sort of one of the markers of success
- 20:13you know there were these companies that were like oh
- 20:15what's yeah that we're going to build on it and then I feel like
- 20:18it sort of happens and falls out of the conversation chart out
- 20:22crisper and what it means for sort of your thesis here, we
- 20:28kind of set up intersection of two technologies Geez that very
- 20:30much so kind of follow up a little bit of a truism or
- 20:33saying, which is that their magic until they work and then
- 20:35they become yesterday's news. And in some ways that's true of
- 20:38AI in ml and so many ways. That's true of biology and
- 20:42chemistry and the life sciences what's possible today because of
- 20:45crisper should have our Jaws on the floor, all the time.
- 20:49It's absolutely magical in 2014. Eric, when you were covering it,
- 20:53that was the very kind of tip of the iceberg of our ability to
- 20:55really kind of be precise and have the equivalent of a copy
- 20:58and paste and or scissors With text on the kind of genetic this
- 21:02one would, you know, George Church was what trying to store
- 21:04like book type information in type information, right?
- 21:09And it really mammoths and all sorts of things.
- 21:11And the reality is today, you might not still hear about
- 21:16something like, crispr cas9 and the news it has and so many
- 21:19ways, kind of become that proverbial yesterday's news, but
- 21:22every modern research lab biotech and Pharma is using
- 21:26crispr on a daily basis if they're doing any sort of
- 21:29research at all. All and crispr is exactly kind
- 21:31of equivalent or analogous to kind of nons Point earlier where
- 21:34it really has followed Moore's Law, curves and costs, and
- 21:38scale, and Fidelity, and reproducibility and so it's
- 21:40becoming increasingly powerful and it's giving scientists and
- 21:43researchers and Drug hunters and developers increasing leveraged
- 21:47in what they're doing. It's just no longer in the news.
- 21:49Adam actually had when he was a PhD in the lab, you know,
- 21:52hundreds of years ago, the alternative the alternative, you
- 21:59know, way For the, the sort of mechanism of crispr was invented
- 22:02to get the same kind of genetic changes.
- 22:04And sells it would take them months to order these cell
- 22:08lines. He is back for years.
- 22:11Yeah. You know, it could we are using
- 22:12these molecular tools, you know, every lab today has access to
- 22:15those types of edits in a day or two day.
- 22:18Turnaround. So that kind of enabling
- 22:21technology, you're not going to hear about because it's there's
- 22:23no sort of publicly traded company.
- 22:25That represents that technology, it's more of a tool that is
- 22:28essentially using a Single lab but it speeds up the process as
- 22:32feeds up. A lot of the sword inputs into
- 22:35experimentation and allows those labs to run much much faster.
- 22:39Right now. Today there are companies run a
- 22:42clinical trials and using crispr to treat diseases and
- 22:47genetically modified human beings, right?
- 22:49And so when you talk about this downturn in public you know
- 22:53momentum or press or conversation mean, maybe I'm a
- 22:58geek and I a decal. These things.
- 23:00But that like, that, that science fiction to science,
- 23:02fact, ride that, like, your Gene were editing people today in
- 23:06order to cure diseases. That's mind blowing and that's
- 23:09coming. You know, much more in the
- 23:11future. I mean, I touched on.
- 23:13So we sort of did sort of almost bespoke drugs, AI for Discovery.
- 23:20I promised three. So I don't want to deny the very
- 23:22attentive listener that we've talked about tons of wonderful
- 23:26things. Anyone else have a another area
- 23:28where you're optimistic thick sort of over the next two
- 23:30decades. It might be fun to talk about
- 23:33something like modern app and kind of covid vaccine as as an
- 23:36existence proof for sure as a kind of indicator of what's
- 23:39possible. If we rally the right resources
- 23:42around something and that was a again if you look at the history
- 23:46of our ability to develop vaccines it, seriously taking
- 23:50you know years, if not decades and hundreds, if not billions,
- 23:54if not tens of billions of dollars of research and
- 23:56development costs to develop vaccines.
- 23:58And so when covid first Around. There was a very smart and
- 24:02sophisticated group of people whose that we're kind of fucked
- 24:05like. But it's Gonna Take 5 to 10
- 24:07maybe 15 years. If we ever find a vaccine for
- 24:09this thing, and if you look at how modern actually developed a
- 24:13vaccine within within 24 hours of sequencing, kind of the
- 24:16epitope or the protein, they had actually developed, what
- 24:19ultimately would become the first vaccine that they took to
- 24:22humans, and all of the kind of time after that was in and
- 24:25around. Synthesizing it in and around,
- 24:27testing it in various kind of in vitro, and in Vivo.
- 24:29Models and then ultimately also testing it and increasing kind
- 24:32of scales of patient populations, but the ability to
- 24:36within 24 hours actually find and develop the vaccine or the
- 24:40molecule in this case again there's this kind of he's
- 24:44persona non grata as a comedian in many ways but Louis c.k. has
- 24:48has this big from I remember and met when I was in my early 20s,
- 24:51about every time we fly, We complain though.
- 24:54The Wi-Fi is not fast enough, like I like the hostesses and
- 24:57bringing me my soda. Like I feel squeezed in the And
- 25:00you know, in the middle row in the middle seat, but like holy
- 25:02fuck your into are going. 600 miles an hour across the planet.
- 25:06And, and that's, that's how we should feel about what's
- 25:09happening in biology and was, and can leave is also happening
- 25:11on software in ml and Ai. And the interesting thing is,
- 25:14like, they're compounding and rates that I think non Adam, and
- 25:17I also sometimes feel like we're the only people who are seeing
- 25:20what's happening and it's unreal and it should yield like
- 25:23unwavering optimism and excitement, but it's often time
- 25:26easy to get lost kind of in the minutiae of the details and or
- 25:29take it for granted. David, the reason why it does
- 25:31question is really important is that to the general public who
- 25:34are not in these Labs or you know, working hand-in-hand with
- 25:36these companies you know they're not seeing the results and and
- 25:39essentially commercially approved, drugs are the last
- 25:43indication of progress in the Biotech Industry.
- 25:46You know we talked about an acceleration of experimentation
- 25:49and acceleration of asset Discovery and you know crafting
- 25:53new compounds that are more targeted more powerful but those
- 25:57are still moving down the pipes in So I would say the larger
- 26:02prediction is essentially there are only four thousand
- 26:04commercially approved drugs in the market globally.
- 26:08And that number is sort of steadily ticking up, but you're
- 26:11not seeing that exponential growth yet.
- 26:14In 5-10 years, we're going to see the output of all of these
- 26:17sort of generational leaps and tools.
- 26:19And we're going to see this era of really unmatched productivity
- 26:23and that that directly affects patients.
- 26:25If you have many companies, where it feels like, what
- 26:28they're doing is going to touch, Touch the sort of the masses or
- 26:32is it always the case? That Healthcare is sort of
- 26:34helping the very sick and so it's only really going to come
- 26:38up in your life when you want some sort of disease treatment.
- 26:42Or the very well, you know, it is things are like, if I think
- 26:46all of us. I mean, frankly, if you interact
- 26:48with the healthcare at all, you probably rated as a very low
- 26:51NPS. You hate going in, you're always
- 26:54in lines, like you go from a doctor to a specialist back to
- 26:57a, you know, a PCP and they all lose their data.
- 27:00There's no kind of information flow with them.
- 27:01Healthcare is the largest sub-sector of the GDP.
- 27:05It is the only sub-sector of the GDP that doesn't have increasing
- 27:08economies of scale and productivity brought to it from
- 27:11digitized. In and technology and
- 27:13importantly. 90% of it is on Clinical Services is in
- 27:17healthcare kind of patient care settings and so it's when we
- 27:20don't have the ability to treat or to diagnose a disease early,
- 27:25they end up becoming so bad so catastrophic that these patients
- 27:28end up in these kind of heinous, horrible kind of circumstances
- 27:31and that's where it really where the costs come up.
- 27:33If we do our jobs right in, as non mentioned earlier, if we
- 27:36move from a world of intense kind of Discovery and
- 27:39development scarcity into a world of Of radical abundance
- 27:43both in terms of biology and chemistry kind of Discovery.
- 27:45But then also in the downstream effects of therapies, kind of
- 27:48coming down the pike. If that happens, it starts to
- 27:50change. Kind of the cost curves were no
- 27:52longer spending billions and Kennelly globally.
- 27:55Trillions of dollars on Health Care Services.
- 27:58Curing, patients are attempting to at least manage illnesses.
- 28:01Once it's too late but retreating upfront as early as
- 28:04possible, those patients. So that those diseases never
- 28:07manifest or never mature into those, kind of end States and
- 28:10Eric, like a Don't want you to think about what we're talking
- 28:13about is just for those that have access or just for these
- 28:16rare diseases to companies that, you know, we started our prior
- 28:20firms at Lux, you know, one was a company called Calliope a
- 28:22where I, you know, I was factually founding CEO of that
- 28:25was focused on the gut brain axis.
- 28:27This new kind of two-way communication Highway between
- 28:30the gut and the brain and that was deploying all these
- 28:32cutting-edge Technologies like single cell sequencing organized
- 28:34technology. Yes, kind of machine learning on
- 28:36top of their data sets and their Atlas, that they generated, but
- 28:39they were focused on, you know, metabolic diseases.
- 28:41Has obesity diabetes, things about IBD and Crohn's
- 28:45gastrointestinal disorders, right?
- 28:47And then thinking about other mental disorders because you can
- 28:49there's a world where you treat, you know, mental disorders
- 28:51through your gut because it's connected.
- 28:54The second company that we found, it was a company called
- 28:56Carl neurosciences. We were part of the founding
- 28:58team there. It's an amazing company over in
- 29:01Seattle, Ian pycon and the founders there Andrew dervin
- 29:04their incredible you know technologist scientists they're
- 29:07focused on the outside. That's right and Parkinson's and
- 29:10so you know depending Knowing these cutting-edge Technologies
- 29:13like viral Technologies Imaging Technologies to automate scale
- 29:17and do throughput in drug. Discovery is not just targeting
- 29:21the very, very unique, you know, diseases.
- 29:24It's targeting. You know, it's permeating across
- 29:26the entire disease Spectrum, whatever that disease is.
- 29:29Yeah. And I think you can think about
- 29:31you know the average patient and the way we think about health
- 29:34care is very reactive. You know, as I've mentioned you
- 29:38know, most patients are not self-aware around their health
- 29:40care into until they Perience symptoms and usually severe
- 29:43symptoms and then through managed through this highly
- 29:45complex and inefficient Health Care System.
- 29:48But the reason that is is really because of a lack of specificity
- 29:52and Diagnostics and an awareness of what's happening in health
- 29:55progression. So the human body is just a
- 29:58highly complex system. It's an engine and it's
- 30:03essentially this bag of chemical reactions.
- 30:05Sort of happening at a rate of billions per microsecond all
- 30:09over your body and then once A while things go haywire and you
- 30:13experience a symptom and I think for the average patient and the
- 30:17health care, the health care industry is with more precise
- 30:20medicine comes along with it more precise diagnosis and
- 30:24preventive Diagnostics. So we're moving into a space
- 30:27where I think it's entirely reasonable within the short
- 30:31term. You know, a 10-year window where
- 30:33there's an annual checkup will come with a blood diagnostic
- 30:36that gets funneled into this sort of genomics and proteomics
- 30:40Analysis. To sort of pinpoint issues that
- 30:43are happening before you express disease before your symptomatic,
- 30:47before you have to go see a specialist and medicine is given
- 30:50to you at that stage. So, to a normal person, I think
- 30:54that really changes their experience with Healthcare.
- 30:56One of the amazing things about one of the things I love about
- 31:00like the iPhone is that it's like a technology that the best
- 31:04version of which is available to sort of the mass public
- 31:08obviously sort of still a wealthy set of people in America
- 31:11you know. The Western world but but you
- 31:13know like there isn't this like billionaire phone that is so
- 31:17much better, right? Like the fan awesome.
- 31:20I love needs to be mass-produced for it to work and so there
- 31:23isn't some like secret phone that you're like, you really
- 31:26wish you had with medicine where are we on that or like you think
- 31:30if I'm a 50 year old healthy billionaire versus a 50 year old
- 31:34regular person like what's the gap between the quality?
- 31:39Of my like health is there a lot that Billy Ian Ayres like really
- 31:43can do or they just like poking and prodding themselves with
- 31:46little benefit or what's your sense of the Gap and do you
- 31:49think it's going to grow or Shrink sort of over the next
- 31:52decade? I have some young mice in my
- 31:55freezer that I inject blood from on a regular basis.
- 32:02The blood. Transfusion.
- 32:03Yeah, that was a transfusion as we speak.
- 32:07So what do you think? Yeah.
- 32:11There's a big gap between what a yeah II think the biggest Gap is
- 32:16around the dependency of most people on insurance companies
- 32:21and reimbursements to access health care, both medicines and
- 32:23procedures, and also Diagnostics.
- 32:26And, you know, those in sort of the 1% and whatnot can can take
- 32:30charge of their own health care. So there are a lot of different
- 32:33sort of preventive scans, or diagnostic tests that can be,
- 32:37run that insurance companies would never reimbursed because
- 32:40it doesn't really make sense of Cross their population, a really
- 32:43good. One is a company called /
- 32:45Nouveau, which does essentially a full-body CT scan, and I think
- 32:49it's on the order of two or three thousand dollars, that's
- 32:52not reimbursed. CTS are only reimbursed one.
- 32:54There are symptoms by the healthcare system.
- 32:56If you have sort of symptoms that indicate you might have a
- 32:59tumor or growth in you, then it's beneficial for the
- 33:02insurance company and for the clinics to go image, you, and,
- 33:05and try to locate the problem. But if you, if you have access
- 33:09to that cash pay, you could go Your Provost.
- 33:12And every year, a whole body ZT, you would see the earliest
- 33:15indications of sort of, you know, phase one stage, one
- 33:19cancer is before you would experience any symptoms and it's
- 33:22getting into that short preventive diagnostic.
- 33:24Do you guys album, like, do you do that?
- 33:27Is that you? I have that.
- 33:30I just went to my primary care provider for the first time in
- 33:32five years, I think. Rich people before and it's like
- 33:44the risk of these scan who don't do these scans and like the
- 33:48issue with this scans is, you know, you could scare the shit
- 33:50out of yourself or like. Doctors won't always tell you to
- 33:53do them because you find these false positives and then you
- 33:57drive yourself crazy or another, there's just like lots of
- 34:00downside, still to over testing. So that's why I do.
- 34:03It's a legitimate question. Whether there's this secret sort
- 34:06of medicine or biology world that people are missing for
- 34:10something like the pronovias can until until We actually know
- 34:12what to do with that Downstream data.
- 34:13It's harder to kind of get it kind of insured.
- 34:16It's not to say that it shouldn't be offered to
- 34:18everybody but, but quite frankly, like the things that do
- 34:20past the FDA process to your point earlier, it's the one area
- 34:24in technology or consumer goods where what the poorest of the
- 34:27poor can access today is what the richest of the rich could
- 34:31access 20 years ago. There is exactly kind of this
- 34:34things are forced to go. Generic every drug.
- 34:36That was kind of discovered 20 years ago is now off IP off,
- 34:41kind of Bad life and and essentially kind of should be
- 34:44available at Cost Plus margins in terms of how expensive it is
- 34:48to manufacture that and there's no other technology out there.
- 34:51I really love your kind of example of the iPhone and the
- 34:53laptop. We use the same iPhone in the
- 34:55same laptop that Elon Musk Bezos.
- 34:57Our gates are using right now and like, that's that is that
- 35:00Empower kind of the democratization of Technology.
- 35:03We also use the same drugs by and large there are.
- 35:06And there will continue to be billionaires millionaires on and
- 35:10so forth. You kind of experiment but
- 35:11they're also King on the risk of those experiments themselves to
- 35:14and again until those things are provably efficacious, for a
- 35:18broad population of people, they shouldn't be kind of reinsured,
- 35:22nor should they be kind of approved through a regulatory
- 35:24process, right? I was just talking to Scott
- 35:27sindell, you know, the top guide, any a they raised a 6.2
- 35:30billion dollar fun. And you know, when they
- 35:32announced it, I mean they put Health right in that headline.
- 35:35Like, I think he'll broadly is very popular in like the Venture
- 35:39Capital world right now. Now, I mean you guys have a much
- 35:43more specific sort of lens at it are there parts of sort of the
- 35:48VC, conventional wisdom on health investing.
- 35:52Not any particular which is DC help investing generally that
- 35:55you disagree with, or there's some of these Health bets that
- 35:59you're going to try and steer away from or, yeah.
- 36:01How do you see your approach here?
- 36:04Fitting into the excitement around?
- 36:07Sort of Hell, digital Health would have you broadly in
- 36:10venture. As we think about the
- 36:12digitization of Life Sciences, the entire industry that you
- 36:15know, farmer and biotech and life science.
- 36:17Companies like danaher and Thermo.
- 36:19Consume, that is an enormous opportunity in an enormous
- 36:23industry, right? And so we feel like that's
- 36:26enough to digest on our plate and not have to you know, also
- 36:30focus on partnering with companies that are building.
- 36:33They're doing really interesting things but are you know, selling
- 36:36care coordination tools and Technologies are selling into
- 36:38hospitals or selling to doctors are building the next EMR or Or
- 36:41building the next health insurance company, it is an
- 36:44enormous industry but the one that we feel like we're focused
- 36:48on deserves its sector, Focus fun and that's why we built
- 36:52Dimension and with concentration and focus, we feel like comes,
- 36:56you know, you know better outcomes and you know, greater
- 36:59capture of value as we spoke about some of those firms before
- 37:02the, you know, have done it on being sector Focus.
- 37:04So I'd say that for us, you know, rather than being like
- 37:08incredibly broad throughout the entire Carrie go system.
- 37:12Now our focus is on the life science Industry, I like the
- 37:16dynamic and the life sciences industry where you essentially
- 37:18have completely aligned incentives across all the key
- 37:21stakeholders. So medicines are valuable to
- 37:24develop pharmaceutical companies want to get access to research,
- 37:28want to get access to budding medicine in the making, and
- 37:32biotechs and startups are rewarded for contributing to
- 37:35that progress, and you essentially, all the wheels are
- 37:39turning quite well. I think universally We across
- 37:42both Founders and also generalist species that start to
- 37:46do work in healthcare. There's an under appreciation of
- 37:49how much incentive change incentive alignment and behavior
- 37:53change is required. Even if the technology or the
- 37:57software, the product is developed well in our world, if
- 38:01you develop a medicine that your shows efficacy and is screening
- 38:05well in testing. Well, there was a clear-cut path
- 38:07for it to go through the developmental process and get
- 38:10impatient and generate revenue and And build value that's often
- 38:13not the case in healthcare where you have to convince me to
- 38:17regular people to change their behavior, or you have to
- 38:19convince hospitals to change their behavior or insurance
- 38:21companies. So, I think venture over the
- 38:24last decade especially in sort of a cheap cost of capital World
- 38:28funded, a bunch of companies that are taking real shots at
- 38:31changing the healthcare system and that's good for everyone.
- 38:33But in their world, it's not a meritocracy.
- 38:36They have to do work in sort of politics and galvanizing the
- 38:41change. JH in our world, everyone wants
- 38:43to change, even the incumbents you know, want what we're
- 38:46talking about. Eric, your question on the kind
- 38:49of like any, a in the broader Venture ecosystem, one having
- 38:52just kind of grown many, many, many many, many gray.
- 38:54Hairs with what feels like increasing arthritis, having
- 38:57raised 354 Dimension. One, we are humbled and in Shock
- 39:02and Awe by Scots and Eleni a 612 bit like the, yeah, it's hard to
- 39:07compute what that looks like and kind of the trust and conviction
- 39:11and If that, they must have shown over many, many, many
- 39:13decades of really kind of intense investing, but they're
- 39:16all piece together that, especially in today's
- 39:17environment. So kind of all hats off.
- 39:19On the other hand, we saw directly at our prior firms.
- 39:23And then also, from the eyes of the entrepreneurs that we had
- 39:26backed that Founders today, who are building at this
- 39:29intersection of technology and biology in the Life Sciences,
- 39:31they are stuck between a rock and a hard place on either end.
- 39:36They have a Faustian bargain, they can go to, you know, an any
- 39:408 which is might have, you know, five or ten percent of their GPS
- 39:44spending time in the Life Sciences they might have their
- 39:45med tech device met device team in.
- 39:47D.c. the might have it biopharma team on Sand Hill, so on and so
- 39:50forth. But there's not
- 39:51cross-collaboration ultimately when the founders go in there,
- 39:54there's not kind of firm-wide top-down conviction.
- 39:57It is one of the many strategies that that kind of firm deploys,
- 40:01weaned on Adam. And I we kind of started joking
- 40:04early on. When we launched, I mentioned
- 40:05food, gonna go into meetings and say, two things, we'd quack
- 40:07quack, quack, like a Mighty Ducks reference, be we fly as
- 40:11one. Now the on the other side Eric
- 40:13you do have is not mentioned kind of the true small biotech
- 40:15investors whether they're in Seattle or Cambridge, or San
- 40:18Francisco or San Diego, so on and so forth, the atlases.
- 40:20The Polaris is the flagships, the arches of the world and
- 40:23again, loads of respect what they have done.
- 40:25We were just at dinner last night, but you're catching Us in
- 40:27Utah right now for a GP Corpus kind of our team off-site, but
- 40:30we were sitting there all mr. Damon, by the way, and we sat at
- 40:33dinner last night, kind of, in 44 salt, 30 minutes, really
- 40:36talking about kind of what they are uniquely able to do and
- 40:39their historical success rates which are Impressive.
- 40:42But they have also at the same time.
- 40:44Simultaneously been historically, very reticent to
- 40:48accept technology. They've been luddites with
- 40:49respect to technology and they're starting to come around.
- 40:52But we believe it's not just a muscle or a capability that you
- 40:55can Frankenstein on both an investment firm.
- 40:58And on to the actual company, needs to be kind of organic and
- 41:00built from scratch. Realizing the new world that be
- 41:03stated in terms of your fund. Specifically, do you think there
- 41:06will be deals that you do where the logical follow-on round
- 41:11comes? From those sort of Old Guard
- 41:13biotech funds? Yeah, I mean I think you think
- 41:17about Job mentioned one of them before like what Bob and his
- 41:21team at Archer doing is incredibly impressive.
- 41:23And I think, you know, Bob starts to think about the world
- 41:26Notch not to think about the world where they, they want to
- 41:29get involved in some of these broader discovery engine
- 41:32platforms that we invest in solely across the biotech space.
- 41:35They are intrigued about the software, the tools, and the
- 41:38instruments that are kind of digitally native, you know, our
- 41:40Cloud for And so, you know, and I think there's a ton of room to
- 41:44collaborate. They won't be, you know, not all
- 41:45of them. I think is probably the best
- 41:46answer to your question. You know, some are focused on
- 41:49kind of those building biotechs that are focused on a single
- 41:52asset or a dual asset or, you know, low-hanging fruit that
- 41:55still continues to exist in BIO and Drug Discovery.
- 41:58And that's very lucrative to some of these firms in their
- 42:01playbook and they've created a ton of value and candidly,
- 42:04created a ton of really impressive, you know,
- 42:07therapeutic drugs that have real treatments out in the real world
- 42:09so but that you know some of them We'll see.
- 42:12You know, what we're doing is too far, you know, too far of a
- 42:15stretch for within their own strategy but some will you know
- 42:18will co-invest with and partner up with and you know I was
- 42:21texting back and forth with Bob you know a couple of nights ago
- 42:23saying let's find deals to do together.
- 42:25There is an argument that sort of the low interest rate
- 42:28environment was like, the best time for this sort of futuristic
- 42:33technology investment that was sort of the window.
- 42:36And now with interest rates going up, people are much more
- 42:40oriented around Prophets like SAS Company software companies,
- 42:44where there's no question that, they'll be able to figure out
- 42:46how to monetize need to make profit sooner.
- 42:49If that's the mentality of the moment, will there really be a
- 42:52lot of appetite outside of, you know, your fund to bet on
- 42:57companies where maybe the follow-on around, you know, the
- 43:01company still doesn't have revenue and still sort of a
- 43:04project? Yeah I mean II, think that what
- 43:08we're recognizing is new Industries are Is the best
- 43:12investment opportunities because there's true Alpha, there's
- 43:15inconsistency of understanding, there's intensity of
- 43:17underwriting and investors by their nature, should be seeking
- 43:21out those opportunities especially in Venture and growth
- 43:23Equity. So yes, cash is more expensive
- 43:27today than it was two years ago. You're going to start to see a
- 43:30and you're already seeing us were returned to pre 2020 levels
- 43:35in terms of fundraising activity funding levels round Dynamics.
- 43:39But that doesn't really take away from From the broader
- 43:43worldview, which was job mentioned.
- 43:45This is the largest category of the GDP.
- 43:47There's real dollars going into life science and biotech up and
- 43:51downstream, you know, in preclinical development in,
- 43:54selling off Assets in selling data, access into these these
- 43:58Discovery engines and what insights they find.
- 44:01So along the way, you know, we think our businesses.
- 44:04Do you inflict value in a short amount of time?
- 44:07They're not these sort of Science Fiction.
- 44:10Deep J curves. Where they Need a decade of
- 44:13funding and sort of, countless hundreds of millions of dollars,
- 44:16you know, they're showing platform progress between cdna,
- 44:20they're starting to develop medicines between A and B.
- 44:22They're getting human data between B and C.
- 44:24So, along the way those are real Milestones, they're not SAS
- 44:28Milestones, but to this broader industry, which is a huge
- 44:31category, the most acquisitive industry in the world.
- 44:35Those Milestones accrue value, you to farm a biased as one
- 44:38assets. They buy things to assets.
- 44:40So, you know, we're here. Your help guide them and we
- 44:42think there's a whole world of investors that understand those
- 44:46milestones and it's certainly our job to help sort of
- 44:49galvanized a space. And to standardize a kpi is, or
- 44:52were having this why Johnny's, right?
- 44:54Okay. Yeah, right.
- 44:56So it's we play a role there. We just had a dinner that
- 44:58earlier this week. With 20 growth investors,
- 45:00talking about this exact space, the intersection of technology,
- 45:03and life science and a span from growth Equity to hedge funds, to
- 45:07Sovereign, wealth funds, and they're all interested in the
- 45:09space. They know that innovation.
- 45:11It's coming, they see it. Sort of empirically just
- 45:14through, you know, where the practitioners are and what's
- 45:16happening. So we're very confident in
- 45:18Downstream Capital, it will be disciplined capital and I
- 45:22actually think that's a good thing, zero interest rate
- 45:24environments with infinite cache.
- 45:26Don't build companies. I actually think that better
- 45:29companies are built during times.
- 45:31Like were, you know, kind of where we're headed right now
- 45:33with a real Theron's fit in your investment thesis.
- 45:36And will we ever see one we backed at our old firm a company
- 45:40Thrive lat? Exactly the firm that will not
- 45:43be mentioned. You guys don't say any more
- 45:46Roxanne was doing blood draws for multi
- 46:04cancer kind of diagnosis. And so that's not quite there
- 46:07knows but it's kind of adjacent and those Technologies are
- 46:11Increasingly on the comp it will happen at some point again.
- 46:14There's no scientific reason why that's not possible.
- 46:17Obviously, like finding entrepreneurs who aren't
- 46:19fraudsters, who aren't writers who aren't the equivalent of,
- 46:22you know what the Elizabeth Holmes was or and or SPF at ft x
- 46:25was 2 and then stewarding them really underwriting but the
- 46:28technology the science and ultimately the business how you
- 46:31know, raising a people said it couldn't be done, you know it's
- 46:35like you start every every old-school Venture firm right
- 46:38now is saying no the new funds are in trouble, you know?
- 46:41And you guys are pretty big, new first fun.
- 46:44So congratulations. What were the War Stories?
- 46:47What's the mood? Among the limited partners?
- 46:49And how did that play out here? The size of the first thing?
- 46:52I, you know, I think this is back to one of your original
- 46:54questions is, how do we come to be right?
- 46:55We've known each other for a decade where friends are havin
- 46:58none of live together. You know, it's been a decade
- 47:00long and want to say conversation but sometimes, you
- 47:03know, robust intellectual debates as well, chiseling away
- 47:06the thesis but when we started, and when we left our phones, we
- 47:09left with nothing right? We had our Reputation.
- 47:11We had our network but you know, we had an idea of where we want
- 47:15to go, but we didn't have an anchor LP or we didn't even have
- 47:18a name. And, you know, none shifted his
- 47:21family over to from California to New York for a month.
- 47:24And you know, we put ourselves into Chris's spacer Runway and
- 47:29just hunkered down and came up with, you know, everything from
- 47:32thesis and collateral to thinking about how we wanted to
- 47:35position ourselves, what was the message?
- 47:37And as someone that like hasn't truly, Pass jumped into like a,
- 47:42you know build it from scratch entrepreneurial everything.
- 47:45On the line situation, it was the most exciting, you know,
- 47:50time of my life and I think our lives, I'd speak to, you know,
- 47:53for the for the three of us as well.
- 47:55So there's a lot of us, any money on lawyers, now that I
- 47:58have my own like newsletter. I mean, I don't know, but it's
- 48:00just like you sir. All the random shit, you need to
- 48:03get other people to do you like? Oh no.
- 48:05Hi Sierra. Hi Arnold.
- 48:12They're actually listening to this and billing us right now
- 48:23that are kind of friends, peers, contemporaries and Industry.
- 48:27Kind of really came as kind of supporters Advocates advisors
- 48:31mentors for us as we launched. It was something that we
- 48:34absolutely needed. We didn't know we needed, but in
- 48:37retrospect we absolutely needed and it just like we had no idea.
- 48:41Don't even ask for it or that it would happen.
- 48:43And if there's ever a chapter written about dimension in some
- 48:45future kind of Anthology which I hope one day, we build a firm
- 48:49that you know, demands that sort of attention an entire chapter
- 48:52will be on Samuel and Chris and Matt at Paradigm and Weston and
- 48:58in so many of our friends who on day one, both gave us an
- 49:02exceptionally strong stewardship and advice and mentorship and
- 49:05guidance. But then also were so generous
- 49:07with their most scarce kind of resources which is there L packs
- 49:10in their ER and and their investors.
- 49:13And so that gave us critical kind of fuel entering what was
- 49:18as non atom and you have already discussed a buzz saw of a market
- 49:22and we would not be here without them.
- 49:24So that that was just like the coolest part, getting the first
- 49:28anchor, you know, what can you say about that?
- 49:30Or that must have been quite the experience to have sort of an
- 49:35anchor. It was a very good idea late.
- 49:37We start raising fund raise. Go ahead.
- 49:41No, no, I was just telling about the email who was fun to her.
- 49:45It was one of the leading allocators on the planet and
- 49:48they were Progressive and understood kind of the, exactly
- 49:51the kind of this Confluence of Technologies between the life
- 49:54sciences software, Automation, and Hardware.
- 49:56They were paying attention to the space and to their credit.
- 49:59They were amongst the first people who reached out to us and
- 50:01who we spoke to, and then they remained the largest kind of
- 50:05check in our fondant. So, you know, and they just send
- 50:08you an e-mail, they were like, all right, we're going to put
- 50:09this much in or what really. At us and known us for a long
- 50:12time. The old pre about throughout our
- 50:15prior firms, locks and obvious and they move quick.
- 50:18We had a number of conversations we met there.
- 50:20It was a little bit like the rose.
- 50:21Obviously, the roles reversed, right?
- 50:22They saw a really interesting opportunity, they wanted to
- 50:25really partner and they moved with ultimate conviction.
- 50:27So you plant like a start-up, you're like, I don't know.
- 50:29There are a lot of people GT's don't have that leverage.
- 50:37I'll tease know it takes. It takes so many kind about I
- 50:41do. I mean, I'm in Milan, I've been
- 50:44telling some of my founder of friends that raising a venture
- 50:46firm is kind of like raising for a start-up but you need 20 term
- 50:50sheets because of how much most LPS are committing.
- 50:53So right, you get to sort of briefly high-five and celebrate
- 50:57but then it's it's kind of rolling into the next meeting
- 51:00and we just did that for six months straight between me and
- 51:03November. Well this was so much fun.
- 51:05Thank you guys for coming on the podcast.
- 51:07I really enjoyed it and good luck to you.
- 51:10Thank you. It's getting nicer having us
- 51:12big. Thank you for hosting us.
- 51:26Goodbye. Goodbye.
- 51:28Goodbye, goodbye, goodbye. Goodbye.